https://www.live-feeds.com/feed/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2026-financial-results-highlights-multiple-milestones-advancing-broaContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2026-financial-results-highlights-multiple-milestones-advancing-broahttps://www.live-feeds.com/feed/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2026-financial-results-highlights-multiple-milestones-advancing-broa#u166973Sun, 01 Nov 2026 06:46:24 +0000Merck & Co., Inc., Rahway, N.J., USA reported Q3 2026 financial results, highlighting $18.1 billion in total worldwide sales, a 5% growth, with key contributions from oncology and animal health products. The company's cancer treatment Keytruda and new product Winrevair showed significant growth. Merck also presented pivotal data from Phase 3 trials across its oncology pipeline at the ESMO Congress 2026.Why it mattersMerck's financial performance reflects its continued strength in oncology and animal health, with a diverse pipeline of products. The company's results are close